Novo Nordisk (NVO) Seeks Emergency Injunction Against Eli Lilly's Drug Advertising

Key Takeaways

Table of Contents

Novo Nordisk has requested a preliminary injunction in U.S. court to stop Eli Lilly’s advertising for weight-loss and diabetes medications.
The Danish company alleges Lilly’s marketing for Zepbound and Mounjaro contains deceptive dosage comparisons with Wegovy and Ozempic.
According to Novo’s complaint, Lilly failed to mention updated, higher-strength formulations of Novo’s medications that show improved weight reduction outcomes.
The pharmaceutical company wants both an emergency halt to the ads and long-term corrective measures from its competitor.
Eli Lilly has rejected the allegations and stated it plans to mount a strong defense.

On Friday, Novo Nordisk submitted a request for preliminary injunctive relief to the U.S. District Court for the District of New Jersey, pressing for immediate cessation of Eli Lilly’s promotional materials for obesity and diabetes treatments.

NVO stock was down 0.02% on the day, while LLY gained 1.97%.

Novo Nordisk A/S, NVO

This filing represents an escalation in the legal confrontation that Novo initiated earlier this week with its Tuesday lawsuit against Lilly.

The company had previously indicated it would pursue urgent judicial intervention if Lilly refused to withdraw the challenged advertisements voluntarily. That withdrawal never materialized.

The contested marketing materials advertise Lilly’s weight-loss medication Zepbound alongside its diabetes therapy Mounjaro.

Novo contends that Lilly’s promotional strategy inappropriately contrasts the maximum approved dosages of Zepbound and Mounjaro with lower-strength formulations of Wegovy and Ozempic — while failing to acknowledge that Novo has introduced enhanced, higher-dose alternatives of these products.

According to Novo’s position, these advanced formulations produce superior weight reduction outcomes, rendering Lilly’s advertising comparisons deceptive to the public.

The Copenhagen-based pharmaceutical manufacturer is citing violations of deceptive advertising statutes and unfair business practices regulations.

Novo’s Legal Demands

The company is pursuing dual objectives from the judiciary: an interim suspension of the advertisements during litigation proceedings, and an eventual mandate requiring Lilly to discontinue the campaigns indefinitely while issuing corrective public communications.

If the court approves a preliminary injunction, it would suspend the advertisements before final adjudication — a demanding legal threshold to satisfy.

Eli Lilly’s Position

When the initial lawsuit was filed on Tuesday, Lilly dismissed the accusations. The pharmaceutical giant affirmed confidence in its marketing practices and pledged a robust legal defense.

As of Friday’s publication, Lilly had not provided additional commentary in response to inquiries.

Both pharmaceutical giants are competing for dominance in the GLP-1 medication sector, which industry experts forecast could surpass $100 billion in U.S. market value before 2030.

The litigation is currently proceeding in the New Jersey District Court, with the preliminary injunction request marking the latest critical procedural development.

✨ Limited Time Offer